SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-289530
Filing Date
2023-12-06
Accepted
2023-12-06 07:00:57
Documents
12
Period of Report
2023-12-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d12624d8k.htm   iXBRL 8-K 22287
  Complete submission text file 0001193125-23-289530.txt   142790

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ntla-20231205.xsd EX-101.SCH 2848
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20231205_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20231205_pre.xml EX-101.PRE 11260
6 EXTRACTED XBRL INSTANCE DOCUMENT d12624d8k_htm.xml XML 3344
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 231468396
SIC: 2835 In Vitro & In Vivo Diagnostic Substances